Travere Therapeutics, Inc. (TVTX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $42.70: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 20%; Elevated put/call ratio: 5.77; Below-average business quality.
Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FDA-approved FILSPARI (sparsentan) for IgAN and a supplemental NDA under review for FSGS (PDUFA April 13, 2026), plus pegtibatinase in pivotal Phase 3 for homocystinuria.... Read more
Sell if holding. Engine safety override at $42.70: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 20%; Elevated put/call ratio: 5.77; Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 5.6/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Travere Therapeutics, Inc.
Latest news
- Reported Earlier, Travere Therapeutics Upsizes Convertible Senior Notes Offering To $475M Due 2032 With $460M Net Procee — benzinga May 7, 2026 positive
- Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $50 — benzinga May 6, 2026 positive
- Travere Therapeutics Plans To Offer $400M Senior Convertible Notes Due 2032 — benzinga May 5, 2026 neutral
- Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings — benzinga May 5, 2026 positive
- TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $60 — benzinga May 5, 2026 positive
Generated 2026-05-20T20:21:22Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductFILSPARI10-K Item 1A: 'our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI'
- HIGHSuppliersole source suppliers for FILSPARI and Thiola10-K Item 1A: 'rely on third-party manufacturers who are currently sole source suppliers for manufacturing of FILSPARI and Thiola'
- HIGHpipelinesparsentan FSGS sNDA10-K Item 1A: 'The sNDA remains under review by the FDA with a PDUFA target action date of April 13, 2026.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Volatile — 5.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $42.70: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 20%; Elevated put/call ratio: 5.77; Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $39.89. Score 5.6/10, moderate confidence.
Take-profit target: $46.61 (+8.7% upside). Prior stop was $39.89. Stop-loss: $39.89.
Concentration risk — Product: FILSPARI; Concentration risk — Supplier: sole source suppliers for FILSPARI and Thiola; Quality below floor (3.3 < 4.0).
Travere Therapeutics, Inc. trades at a P/E of N/A (forward 8.6). TrendMatrix value score: 7.2/10. Verdict: Sell.
21 analysts cover TVTX with a consensus score of 4.3/5. Average price target: $54.
What does Travere Therapeutics, Inc. do?Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FDA-approved...
Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FDA-approved FILSPARI (sparsentan) for IgAN and a supplemental NDA under review for FSGS (PDUFA April 13, 2026), plus pegtibatinase in pivotal Phase 3 for homocystinuria. Revenue derives from U.S. FILSPARI sales and milestone/royalty payments from out-licensing partners CSL Vifor and Chugai for ex-U.S. territories.